Home Health Index June Update
While the home health and post-acute care indices were marginally up in June, the S&P outperformed both by a significant margin.
There was plenty of regulatory and dealmaking news in the month, and that news likely affected stock prices in June and will most likely continue to affect stock prices moving forward.
First and foremost, the Centers for Medicare & Medicaid Services (CMS) released its proposed home health payment rule late in the month, which would — if finalized — reduce aggregate home health payments by 1.7% in 2025. CMS also proposed more permanent cuts to the Patient-Driven Groupings Model (PDGM).
This is now three consecutive years where CMS proposed cuts to home health payment.
There is some optimism that cuts can be mitigated through Congress or through legal action before Mom-and-Pop agencies suffer even more, yet much remains up in the air.
“Home health cuts were expected from providers, but the prospect of a third straight year with meaningful reductions in payment spells trouble,” says Joe Lynch, Partner and Managing Director at Stoneridge Partners. “It’s bad news for the public companies, of course. But they’ll likely be able to deal with the impact better, due to their scale. On the other hand, smaller providers will be affected more severely.”
The home health index was up 0.38% in June, while the post-acute care index was up 0.66%. Comparatively, the S&P was up 4.89% month over month.
Home Health Index
The home health proposed rule is a sign that CMS is not giving up on its theories and methodologies, despite vehement disagreement from providers.
Because fee-for-service revenue is generally the firm leg that providers stand on, there’s risk of industry destabilization.
After all, Medicare Advantage (MA) plans — which are becoming a larger payer source to home health providers by the day, due to MA penetration — generally pay far less for home health services.
Meanwhile, there was significant news regarding Amedisys Inc. (Nasdaq: AMED). The company agreed to offload a number of locations to VitalCaring. That deal is contingent upon the deal closing between UnitedHealth Group (NYSE: UNH) and Amedisys. At the same time, Amedisys likely decided to offload these locations in the first place to satisfy regulators concerned about antitrust in the wake of the UnitedHealth Group deal.
Once that divestment deal was agreed to, Amedisys’ stock went up. In June, Amedisys was up just slightly, but it continued to climb in the first days of July.
Meanwhile, Enhabit (NYSE: EHAB) continues to battle with the activist investor AREX Capital Management. The latter wants to replace the former’s board, citing financial underperformance.
Enhabit was down nearly 3% in June.
What comes next is the all-important August annual meeting. That’s where the showdown between Enhabit, which wants to keep its current board, and AREX Capital will come to a head.
Enhabit released some of its earnings somewhat early in July as a way to point to its recent progress.
“Overall, the second quarter of 2024 is on track to mark Enhabit’s third consecutive quarter of business stabilization and successfully positioning the Company for profitable growth,” Enhabit CEO Barb Jacobsmeyer said in a statement. “This momentum underscores the strength of our strategy, disciplined approach to debt reduction and commitment to stockholder value creation.”
Post-Acute Care Index
The Pennant Group (Nasdaq: PNTG), which has consistently and steadily risen over the past year, was down slightly in June.
But that was not due to lack of activity.
In fact, the company is headed eastward for the first time after agreeing to a partnership with Connecticut-based Hartford HealthCare.
Pennant will take over Hartford’s home health and hospice operations, which will greatly expand its footprint. The company previously did not have locations east of Wisconsin.
“We have deep admiration for Hartford HealthCare and the commitment to home-based care it has long demonstrated through HHCAH,” Pennant CEO Brent Guerisoli said in a press statement. “We are thrilled to collaborate with Hartford HealthCare and contribute home health and hospice expertise to Hartford HealthCare’s impressive integrated care system. Hartford’s selection of Pennant is an honor and testament to the effectiveness of our unique operating model that empowers local leaders to transform operations and provide life-changing service in their communities.”
Pennant continues to remain extremely acquisitive.
The same goes for Addus Homecare Corp. (Nasdaq: ADUS), which was up slightly in June, and BrightSpring Health Services (Nasdaq: BTSG), which was also up about 1%.
Aveanna Healthcare Holdings (Nasdaq: AVAH) has been less acquisitive in comparison to its post-acute index peers, but was up the most in June – by 5.75%.
Quote of the Month
“We know nature plays an important role in human health, but behavioral health and health care providers often neglect to think about it as an intervention.” Lead Researcher Joanna Bettmann, a professor at the University of Utah College of Social Work.
Read the Full Article Here: Natural Medcine: Head Outside for Better Mental Health
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
- Amedisys (AMED)
- Enhabit (EHAB)
Here are the results of the stock prices for the past two years:
| Company | 6/30/24 | 1 mos change | YTD change | 6/30/23 | 6/30/22 |
| Amedisys | 91.80 | +0.71% | -3.43% | 91.44 | 105.12 |
| Enhabit | 8.92 | -2.94% | -13.82% | 11.50 | – |
| HH Index* | 50.36 | +0.38% | -4.45% | 51.47 | 130.43 |
| S&P | 5535.75 | +4.89% | +16.06% | 4450.38 | 3785.38 |
Enterprise Value (EV)
| EV (in M) | 2024 | 2023 | 2022 |
| Amedisys | 3380 | 3420 | 4210 |
| Enhabit | 1020 | 1180 | – |
| HH Index Total | 4400 | 4600 | 9890 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
| Company | 2024 | 2023 | 2022 |
| Amedisys | 150% | 153% | 189% |
| Enhabit | 97% | 111% | – |
| HH Index Average* | 124% | 132% | 220% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these seven publicly traded post-acute care companies, all listed on the NASDAQ:
- Aveanna (AVAH)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Enhabit (EHAB)
- Brookdale Senior Living Inc. (BKD)
- Brightspring (BTSG)
Here are the results of the Post-Acute stock prices for the past two years:
| Company | 6/30/24 | 1 mos change | YTD change | 6/30/23 | 6/30/22 |
|---|---|---|---|---|---|
| Amedisys | 91.80 | +0.71% | -3.43% | 91.44 | 105.12 |
| Addus | 116.11 | +1.13% | +25.05% | 92.70 | 83.28 |
| Pennant | 23.19 | -1.49% | +66.59% | 12.28 | 12.81 |
| Brookdale | 6.83 | +1.79% | +1.79% | 4.22 | 4.54 |
| Enhabit | 8.92 | -2.94% | -13.82% | 11.50 | 22.97 |
| Brightspring
Aveanna |
11.36
2.76 |
+0.98%
+5.75% |
–
+2.99% |
–
1.69 |
–
2.26 |
Enterprise Value (EV)
| EV (in M) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Amedisys | 3380 | 3420 | 4210 |
| Addus | 2150 | 1600 | 1580 |
| Pennant | 1040 | 689 | 703 |
| Brookdale | 574 | 522 | 564 |
| Enhabit | 1020 | 1180 | – |
| Brightspring
Aveanna |
4780
1830 |
–
1640 |
–
– |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
| Company | 2024 | 2023 | 2022 |
|---|---|---|---|
| Amedisys | 150% | 153% | 189% |
| Addus | 198% | 164% | 178% |
| Pennant | 181% | 142% | 157% |
| Brookdale | 189% | 185% | 210% |
| Enhabit | 97% | 111% | – |
| Brightspring
Aveanna |
51%
95% |
–
91% |
–
– |
This graph displays 24 months of Post-Acute Care Index performance.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Yahoo Finance. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index June 2024 | Stoneridge Partners)
Recent Transactions From Around The Country
- NeuroFlow acquired Owl, a provider of measurement-based behavioral health care.
- Bristol Hospice has acquired Mississipi-based Mid-Delta Hospice.
SOLD by Stoneridge!!!
- Stoneridge Partners is proud to announce the successful sale of a Home Hare Agency in Kansas
- Stoneridge Partners is proud to announce the successful sale of a Healthcare Company in Pennsylvania
View Stoneridge closed transactions on our Website.
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Fully licensed and accredited behavioral health clinic. Licensed for outpatient substance abuse and mental health therapy. Other license categories are easy to add. Credentialed with...
Medicaid wavier provider. Serving six counties in south central PA for 25+ years. Licensed to provide CHC, Attendant Care ACT 150, and OBRA Waivers. $262k...
Medicare-certified home health agency. $3.2M in LTM revenue. Medicaid programs comprise nearly 65% of the revenue. VA and private insurance. 4 locations serving 21 counties.
Hospice. 160+ ADC and growing. Multiple locations. No CAP issues.
Independent home health provider. $16.8M LTM in revenue with 13.1% EBITDA. Organic growth of 16.7% over the last 3 years. 44% traditional Medicare, 49% Medicare...
Medicare-certified home health agency. District 4. Accredited. No census.
Home care agency specializing in Medicaid family-supported services. $10M in revenue/$3M EBITDA. 10-year history. Locally acclaimed.
Medicare-certified home health agency. $15M+ in revenue. All skilled. Experienced leadership team. Accredited.
Home health and home care agency providing care to Medicare, Medicaid LTC Waiver, Pediatric and Advanced Neurological patients. $4.5M in revenue. AEBITDA of over 12%. ...
Hospice and IPU. $5.5M in revenue. Deep community ties in a major MSA. Highly dedicated and trained staff.
CHAP Accredited home health provider and hospice license. $5M+ in revenue. Great EBITDA margins in major Nevada MSA. Multiple specialty programs, great growth, and clean...
Transitional living, outpatient SUD, and mental health disorder treatment provider in major Nevada MSA. $2.1M in revenue. Solid EBITDA margins & exclusive contracts with state...
Home care company. $6M in revenue. Non-medical. Medicaid. Family Caregivers.
Home health & hospice. $10M in revenue. Great referral sources. Well-established. On HCHB.
Home care company. $7M in revenue. Private pay, non-medical. Accredited.
Medicare and Medicaid-certified home health agency. Approx. $400k in revenue. Central Arizona.
Non-medical home care agency. $900k+ in revenue. Profitable with large service area. Private duty & Medicaid, newly VA credentialed. CQL accreditation.
Professionally operated home health agency. $1.8M in revenue. 20% EBITDA margins. 20+ years in the Houston market.
Nurse registry. $3M in revenue. 100% private pay & LTC. 100% non-medical. Districts 9 and 10.
Home care franchise. $1.3M in revenue. 13+ years in business. Large territory with growth potential.
Outpatient behavioral health provider. $4.5M+ in LTM revenue. Year-over-year revenue growth. Growth/expansion opportunities with a new location and new services. Licensed to serve a total...
Nurse registry. $7M in revenue. 100% private pay. Primarily non-medical home care. District 9.
Medicare-certified home health agency. DFW area. No census.
Medicare-certified hospice agency. Licensed to serve the entire state of Pennsylvania. No census.
Long-established Medicare/Medicaid home health agency with multiple locations. $7.3M in revenue. Good payor mix. On Homecare Homebase.
Home Health / Ohio / Popular
Home health agency in 2 states, one a CON. $3M+ in revenue. Good payor mix. 5-star patient survey rating.
I/DD provider offering SCL & FHP services. $3M in revenue. Recent rate increase. Strong history in their community.
Behavioral health provider. $5.5M+ revenue with solid EBITDA margins. Leading edge service provider and with proprietary state contracts. Unique combination of service options and contracts...
Behavioral Health / Maryland / Popular
Medicaid/Medicare home health & home care company. $2.5M in revenue. Well-established. Stable revenue. Profitable year-over-year.
Home Health / Connecticut / Popular
Designer/Distributor of innovative, therapeutic, health and wellness personal products. $1.5M+ in revenue. Launched in the US and UK, now launching into the EU. Nearly 7,000...
Staffing Agency licensed to provide staffing services in 6 states. $ 2.4M+ in LTM revenue. Significant long-term contracts with providers in the Care-At-Home space, Health...
Other / Massachusetts / Popular
Homecare agency. $6.5M+ in revenue. Located on Long Island. Blend of Private Duty & Medicaid patients.
Maricopa County hospice. 40+ ADC. CHAP accredited. No CAP or regulatory issues.
Growing ABA (Autism) therapy clinic established in 2020. $1.6M in revenue. Market demand heavily outweighs supply in the area for ABA therapy.
Northeast Oklahoma home health company. $1.7M of revenue and profitable. 95% traditional Medicare. Long history in the area.
Home Health / Oklahoma / Popular
Special education and tutorial provider with limited access contracts. $3M in revenue. Strong relationships with county school programs. Long history in the community, close to...
Medicare-certified home health agency. $1.25M in revenue. AHCA accredited. Broward County (Region 10)
Home Health / Florida / Popular
Medicare-certified home health agency. Region 7, including sought-after Orange county (Orlando). Minimal census.
Home Health / Florida / Popular
Skilled home health agency. Servicing Central Florida for over 20 years. Census approximately 35.
Home Health / Florida / Popular
Occupational therapy practice with 2 offices in Southern California. Hand and upper extremity specialists. 20-plus years in the community. Strong referral relationships. Management and staff...
Other / California / Popular
$5M in revenue. Located in Northern/Richmond VA. Health system-owned Medicare home health. Growing organization.
Home Health / Popular
Medicare-certified home health. Opportunity to establish home health presence in Texas. Minimal census.
Home Health / Texas / Popular
Medicare/Medicaid-certified home health agency. $1.4M in revenue. District 9. Profitable. Accredited.
Home Health / Florida / Popular
Hospice. 45+ ADC. Rio Grande Valley. No CAP or regulatory issues.
$40M+ home care agency with 20+% AEBITDA. Primarily private-duty, non-medical (90%). Medicaid waiver programs. 40% family caregivers. Multiple locations.
Home Care / Pennsylvania / Popular
Home Health Index June 2024 | Stoneridge Partners
From Joe Lynch, Publisher of “Home Health Index.” Joe can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index.
Joe Lynch, Partner and Managing Director at Stoneridge Partners brings over 30 years of healthcare expertise, specializing in mergers and acquisitions, finance, regulatory compliance, and business development. After earning his Business Administration degree from the University of Mississippi, Joe helped expand OrNda Healthcorp’s (now Tenet’s) home health care division.
In 1997, Joe founded Reachout Home Care, a Medicare and private duty agency, which he grew into three operating companies in Dallas and Houston before selling to Humana in 2014 using Stoneridge Partners. After the sale of his own company Joe joined Stoneridge, and for the last ten years has used his industry knowledge to help other owners list their companies and bring them to a successful close. With a proven track record in operations and M&A, Joe brings unmatched experience and
professionalism to every transaction.
For more information, please contact Joe directly at 214-394-0070 or [email protected]. All communications are confidential.